(Press-News.org) A new study by investigators from Mass General Brigham showed that teens and young adults who took varenicline—an FDA-approved, twice-daily smoking cessation pill for adults—are more than three times as likely to successfully quit vaping compared to those who received only behavioral counseling. Results are published in JAMA.
“Vaping is extremely popular among kids, and we know that this early nicotine exposure can make drugs like cocaine more addictive down the line, yet ours is the first treatment study to look at this vulnerable population,” said lead author A. Eden Evins, MD, MPH, director of the Center for Addiction Medicine at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system. “We wanted to help teens and young adults quit, and we found that prescribing varenicline is the best way to do that.”
About a quarter of 18-to-25-year-olds vaped in 2023, and roughly 8% of high schoolers vaped in 2024. Vapes have become a popular alternative to cigarettes with the added challenge of being easy to conceal and easy to use in public places. Yet they contain many of the same familiar health threats, like nicotine addiction, carcinogen and heavy metal exposure, and pulmonary inflammation. Exploring treatment plans is crucial to provide teens and young adults with safe, effective avenues to quit.
To identify such a treatment avenue, the Mass General Brigham team recruited 261 participants aged 16-to-25 into a randomized clinical trial. Participants were sorted into three treatment groups. The first was varenicline, weekly behavioral counseling, and access to a free text support service called “This is Quitting.” The second was placebo pills, weekly behavioral counseling, and the text service. The third was the text service alone. Each group was treated for 12 weeks, then checked on monthly for another 12 weeks post-treatment.
Each week, participants reported whether they had successfully quit vaping, and their responses were verified with cotinine saliva tests. At the end of 12 weeks of treatment and at three-month follow-up, the varenicline group had the highest quitting success rate. At 12 weeks, 51% of varenicline users had stopped vaping, compared to 14% of placebo users and 6% of text-only users. At 24 weeks, 28% of varenicline users had stopped vaping, compared to 7% of placebo users and 4% of text-only users.
These findings demonstrate the importance of medication to help young people who are addicted to nicotine quit vaping, since the varenicline group had three times more success quitting vaping than their placebo counterparts—despite both engaging in behavioral therapy. Further research is needed to explore the potential impact of other therapeutic approaches, as well as to look at even younger people who use nicotine vapes.
Because varenicline is already approved for smoking cessation in adults, it can be prescribed for anyone aged 16 to 25 wanting to quit nicotine vaping.
“Not only was varenicline effective in this age group—it was safe. Crucially, we didn’t see any participants that quit vaping turn to cigarettes,” said Randi Schuster, PhD, founding director of the Center for School Behavioral Health at MGH. “Our findings illustrate the effectiveness and safety of this therapy to address the urgent public health concern of adolescents addicted to nicotine because of vapes.”
Authorship: In addition to Evins and Schuster, Mass General Brigham authors include Corinne Cather, Harrison T. Reeder, Bryn Evohr, Kevin Potter, Gladys N. Pachas, Nancy A. Rigotti, Vanessa Iroegbulem, Jason Dufour, Kelly Casottana, Meghan A. Costello, and Jodi M. Gilman. Additional authors include Kevin M. Gray, and Sharon Levy.
Disclosures: A full list of author disclosures can be found in the paper.
Funding: This study was funded by the National Institutes of Health (R01 DA052583, 3R01DA052583-03S1, and R01DA052583-03S2).
Paper cited: Evins A E et al. “Varenicline for Youth Nicotine Vaping Cessation A Randomized Clinical Trial” JAMA DOI: 10.1001/jama.2025.3810
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
CINCINNATI—Scientists at Cincinnati Children’s along with an international team of researchers have discovered a surprising new connection between gut health and blood cancer risk—one that could transform how we think about aging, inflammation, and the early stages of leukemia.
As we grow older—or in some cases, when gut health is compromised by disease—changes in the intestinal lining allow certain bacteria to leak their byproducts into the bloodstream. One such molecule, produced by specific bacteria, acts as a signal that accelerates the expansion of dormant, pre-leukemic blood cells, a critical step ...
An advanced genomic analysis of a multigenerational family is providing new knowledge about genetic mutations and their transmission, both the variants that are inherited and those that arise anew.
The findings are published today, April 23, in Nature.
“We sequenced and assembled the chromosomes of multiple members of a large, four-generation family to understand how the genetic information changed from generation to generation,” said Evan E Eichler, professor of genome sciences at the University of Washington School of Medicine in Seattle and the corresponding author of the paper.
During the study, lead author David Porubsky was a postdoctoral fellow at the UW. Porubsky ...
The Transdisciplinary Research Areas (TRAs) Modelling and Life and Health at the University of Bonn have presented their €100,000 research prize, entitled “Modelling for Life and Health,” for the second time. The winners—Argelander Professor Ana Ivonne Vazquez-Armendariz and Schlegel Professor Jan Hasenauer—will be using their prize money to study the functions of “scavenger cells” in the lungs at the interface between mathematics and medicine.
The lung’s very own scavenger cells, known as alveolar macrophages, ...
The total economic burden of Alzheimer’s disease and related dementias in the United States will reach $781 billion this year, according to new USC-led research.
This is the first of what will be annual national estimates from the multidisciplinary research team. The team aims to provide the most comprehensive accounting yet of dementia’s growing economic toll. Beyond the cost of care, the model also accounts for lost earnings from patients and care partners who cut back work hours or leave jobs, ...
In an effort to explain a modern medical mystery, an international team of researchers led by the University of California San Diego has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin.
Produced by certain strains of Escherichia coli that reside in the colon and rectum, colibactin is a toxin capable of altering DNA. Now, scientists report that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells—one that may ...
“[…] these data demonstrate that baboons exhibit varying degrees of differences between their chronological and epigenetic ages (i.e., their delta age), allowing characterization of baboons as age-accelerated or decelerated.”
BUFFALO, NY — April 23, 2025 — A new research paper was published in Aging (Aging-US) Volume 17, Issue 3, on March 18, 2025, titled “Epigenetic and accelerated age in captive olive baboons (Papio anubis), and relationships with walking speed and fine motor performance.”
In ...
(WASHINGTON—April 23, 2025) — Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their cancer compared to similar patients who were not taking statins, according to a study published today in the journal Blood Advances.
“This is the first systematic evaluation of the association of statin use with survival outcomes in patients with CLL or SLL ...
In a new report released today, American Cancer Society (ACS) researchers discovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post-COVID-19 pandemic period among adults in the United States. Smoking rates continued a long-term declining trend during the COVID-19 pandemic, but 27 million adults still smoked in 2023. Breast and colorectal cancer (CRC) screening rebounded after decreasing or stalling during the pandemic. However, past-year cervical cancer screening remained lower than pre-pandemic levels, continuing a disappointing pattern in up-to-date screening in the past two decades. ...
Lake Okeechobee, Florida’s largest freshwater lake, plays a vital role in the state’s ecosystem and water management. Spanning 730 square miles with an average depth of just 9 feet, it serves as a crucial water source for agriculture and flood control. Connected to the Everglades through canals, it’s also a popular destination for fishing, boating and birdwatching.
However, the lake faces increasing harmful cyanobacteria blooms, particularly from the toxin-producing species Microcystis aeruginosa. These microscopic algae thrive in warm, nutrient-rich waters and can form harmful algal blooms. Known for their diel (daily) vertical migration, cyanobacteria move up ...
WASHINGTON—The Endocrine Society has selected Yoshitomo Hoshino, M.D., Ph.D., as the recipient of its 2025 C. Wayne Bardin, M.D., International Travel Award for his outstanding ENDO abstract and research contributions to the care of patients with bone health disorders.
The C. Wayne Bardin, M.D., International Travel Award was created in honor of Past President Wayne Bardin, who made remarkable research contributions to both reproductive physiology and contraception throughout his long career. As the winner, Hoshino received a $3,000 travel grant for ENDO and complimentary meeting registration.
Hoshino ...
